Division of Nephrology-Hypertension, Veterans Affairs San Diego Healthcare System, San Diego, California, USA.
Department of Medicine, University of California San Diego, La Jolla, California, USA.
J Clin Apher. 2022 Oct;37(5):497-506. doi: 10.1002/jca.22014. Epub 2022 Sep 29.
Sickle cell disease (SCD) is associated with significant morbidity and mortality, and limits both the quality and quantity of life. Transfusion therapy, specifically automated red cell exchange (aRCE), plays a key role in management of SCD and is beneficial for certain indications in the chronic, outpatient setting. The approach to maintain a successful chronic aRCE program for SCD is multifaceted. This review will highlight important considerations including indications for aRCE, patient selection, transfusion medicine pearls, vascular access needs, complications of therapy, aRCE prescription, and therapy optimization. Moreover, the importance of a multidisciplinary approach with frequent communication between the services involved cannot be overstated. Ultimately, the underlying goal of a chronic RCE program is to improve the quality of life and longevity of patients with SCD.
镰状细胞病(SCD)与显著的发病率和死亡率相关,限制了生活的质量和数量。输血治疗,特别是自动红细胞交换(aRCE),在 SCD 的管理中起着关键作用,并且对某些慢性门诊适应证有益。维持 SCD 成功的慢性 aRCE 计划需要多方面的方法。这篇综述将重点介绍重要的考虑因素,包括 aRCE 的适应证、患者选择、输血医学要点、血管通路需求、治疗并发症、aRCE 处方和治疗优化。此外,涉及相关服务的多学科方法和频繁沟通的重要性怎么强调都不为过。最终,慢性 RCE 计划的根本目标是提高 SCD 患者的生活质量和延长寿命。